Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus / Rhesus macaque B7-2 / CD86 Protein (HPLC-verified), His tag, 1 mg  

Recombinant Cynomolgus / Rhesus macaque B7-2 / CD86 Protein (HPLC-verified), His tag, 1 mg

Recombinant Cynomolgus / Rhesus macaque B7-2, Ala 19 - His 240, expressed from human 293 cells (HEK293), HPLC-verified, His tag

Synonym
recombinant cynomolgus protein, CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

More details

CD6-C52H5-1K

Availability: within 7 days

1 650,00 €

Background
Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Source
Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (CD6-C52H5) is expressed from human 293 cells (HEK293). It contains AA Ala 19 - His 240 (Accession # G7NXR4).
Predicted N-terminus: Ala 19

Molecular Characterization
Cynomolgus CD86 is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 27.3 kDa. The predicted N-terminus is Ala 18. DTT-reduced Protein migrates as 50-80 kDa in SDS-PAGE due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the Cynomolgus CD86 by the LAL method.

Purity
>95% as determined by SDS-PAGE.
The purity of Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (Cat. No. CD6-C52H5) was more than 95% as determined by SEC-HPLC.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 3 months (-20°C to -70°C).

References

(1) Chen C, et al., 1994, J. Immunol. 152 (10): 4929–36.
(2) Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.
(3) Steidl C, et al., 2010, N. Engl. J. Med. 362 (10): 875–85.
The following products could also be interesting for you: